,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['bcsm', 'tnbc']
on the destiny trial: t-dxd .. should not overlook the benefit for the subset of patients with triple negative disease #bcsm #tnbc. the months improvement (more than doubling) in os is beyond thrilling indeed. #asco22 
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet ? endorsement - will summarize oncology news in one tweet each